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Abstract: Complex partial seizures are often refractory to current pharmacological therapies. 
These difficult to treat seizures are typically managed using multiple antiepileptic drugs (AEDs). 
AEDs as a group are frequently associated with significant adverse drug effects, multiple drug 
interactions, and numerous potential clinical complications due to their individual pharma-
cokinetic profiles and unique drug properties. Recently, the approval of vigabatrin by the US 
Food and Drug Administration has necessitated that clinicians re-evaluate these risk-benefit 
relationships and determine where the drug fits within the treatment scheme for the manage-
ment of complex partial seizures. This review will facilitate that re-evaluation through a brief 
review of AEDs used in the treatment of complex partial seizures, followed by a focused 
discussion on vigabatrin.
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Introduction
Seizures are typically categorized into several general classifications, ie, idiopathic, 
genetic (likely polygenic or oligogenic in origin), symptomatic (associated with inborn 
or acquired anatomical or pathological abnormalities), provoked (caused by a definite 
factor that is not anatomical or pathological in nature), or cryptogenic (suspected 
definite cause of unknown origin). These classifications include wide-ranging causes 
of seizure activity, such as chromosomal or gene-based abnormalities, structural 
aberrations in neuronal growth or spatial arrangement, infectious processes, traumatic 
injury, malignancies, metabolic abnormalities, cerebral hemorrhages or infarctions, 
or inflammatory processes.1 Seizure activity is further defined based on the seizure 
type(s), with additional information provided by the signs and symptoms of seizure 
activity and radiological or electroencephalographic findings. Recurrent unprovoked 
seizure activity usually results in a diagnosis of epilepsy.
The classifications and functional descriptions of seizure activity are used clinically 
to inform therapeutic decisions. The treatment of recurrent seizures predominantly 
centers on the utilization of one antiepileptic drug (AED), with possible adjunc-
tive use of a second or even third agent in the case of monotherapeutic failure. The 
  majority of patients with recurrent seizures are successfully managed through the use 
of a single AED. Some patients require successive monotherapeutic trials. However, 
approximately 30%–40% of epileptic patients have inadequate seizure control with 
just one AED, and require the use of adjunctive agents.2 A subset of this group will 
have regular and persistent seizure activity despite reasonable doses of multiple AEDs. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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These seizures are considered refractory to treatment.3 One 
of the most common refractory seizure types is complex 
partial seizures.4 These seizures arise in specific and localized 
cortical regions within one hemisphere and result in impaired 
consciousness. They involve a focal cerebral alteration 
with or without pathological specificity, have asymmetric 
symptoms associated with the site of seizure generation, are 
generally short in duration, and may evolve into secondary 
generalized seizures. Complex partial seizures dramatically 
impact quality of life measurements through functional and 
social limitations imposed by periodic and unanticipated 
impairments in consciousness.
Difficult to treat seizures are of particular concern due 
to the risks of increased morbidity and mortality. Epileptic 
patients have increased risks of accidental injuries, cerebral or 
cognitive damage, and psychiatric or psychosocial   conditions. 
Epilepsy has also been linked to sudden unexplained death in 
epilepsy (SUDEP), accidental death, and suicide.5 However, 
AEDs themselves may cause serious adverse effects, including 
hepatic and/or renal toxicity, cardiac aberrations, blood 
dyscrasias, cognitive or psychiatric impairments, skin dis-
orders, and vision changes. The therapeutic management of 
epilepsy, including difficult to treat seizures, has historically 
been undertaken to balance adequate seizure control with 
drug-related adverse effects.6 Recently, the approval of 
vigabatrin by the US Food and Drug Administration (FDA), 
has necessitated that clinicians re-evaluate these risk-benefit 
relationships, and determine where to place vigabatrin within 
treatment schemes for the management of complex par-
tial seizures. This review will facilitate that re-evaluation 
through a brief review of AEDs used in the treatment of 
complex partial seizures, followed by a focused discussion 
on vigabatrin.
Antiepileptic drugs
Many AEDs have been approved as monotherapy and/or as 
adjunctive agents for the treatment of complex partial sei-
zures (Table 1). This discussion will focus on the medications 
according to their FDA-approved indications, although data 
do exist to support the use of some agents that are approved as 
adjunctive therapy for use as monotherapies to treat complex 
partial seizures. Therapeutic plans are often generated based 
on individual disease and patient factors, and are influenced 
by the experience of clinicians rather than by following a pro-
scribed treatment algorithm. AED activity against complex 
partial seizures is often studied in populations of treatment-
refractory patients, with efficacy measures generally reported 
as the percentage of patients with a $50% reduction in 
seizure activity, or as some time period with the absence of 
seizure activity (for example seizure-free periods of six, 12, 
or 24 months).7 These reported measures of efficacy would 
likely under-represent expected clinical antiseizure activity 
in a normal complex partial seizure patient population. The 
selection of antiepileptic drug regimens may be influenced 
by numerous factors, including seizure type, frequency, and 
intensity, expected response rates, adverse effect profiles, 
therapeutic drug monitoring requirements, possible drug 
interactions, patient age, neurological and cognitive func-
tioning, comorbid conditions, renal and hepatic function, 
and measures of quality of life.
Monotherapy agents for complex 
partial seizures
Phenytoin
Phenytoin has long been considered a first-line agent in 
the treatment of complex partial seizures. It has well docu-
mented antiseizure activity, with studies reporting 30%–60% 
response rates (Table 2).8,9 Despite strong efficacy results and 
widespread clinical acceptance, phenytoin might no longer 
be considered a first-line AED in some clinical practices due 
to its unusual pharmacokinetic properties, requirement for 
regular therapeutic drug monitoring, significant drug interac-
tions, and problematic adverse drug effects.
Phenytoin is highly bioavailable, but with a slow and 
variable rate of absorption that leads to variable maximal 
drug concentrations (Cmax) and times observed to reach the 
Cmax (tmax). It is very highly bound to plasma proteins with 
a small free fraction of unbound drug, making therapeutic 
Table 1 indications of common antiepileptic agents approved by 
the US Food and Drug Administration for treatment of complex 
partial seizures
Monotherapy  
agents
Adjunctive therapy 
agents
Phenytoin
valproic acid valproic acid
Carbamazepine
Oxcarbazepine Oxcarbazepine
Phenobarbital
Topiramate Topiramate
Lamotrigine Lamotrigine
Felbamate Felbamate
Gabapentin
Pregabalin
Tiagabine
Levetiracetam
Zonisamide
Lacosamide
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adjustments necessary for patients with hypoalbuminemia 
and creating the potential for competitive plasma protein 
binding-based drug interactions. Adjustments to phenytoin 
regimens are typically based on successful seizure con-
trol, which typically occurs within a therapeutic range of 
10–20 µg/mL. Phenytoin is highly metabolized, with a widely 
variable drug elimination half-life due to saturable drug 
metabolism at therapeutic doses. Saturable drug metabolism 
is also problematic when perturbations to normal enzymatic 
functioning alter phenytoin concentrations, as occurs in 
numerous drug-drug interactions. Phenytoin regimens should 
be individualized based on clinical response and serum 
concentrations, with special precautions taken whenever 
adjusting drug doses.10
Phenytoin has an extensive list of side effects associated 
with short-term and chronic use. Adverse central nervous 
system (CNS) effects are prominent at therapeutic drug 
concentrations, and include dizziness, drowsiness, lethargy, 
headache, and nystagmus. Dystonia, seizures, coma, and 
death are possible as drug concentrations increase to 
the toxic (.40 µg/mL) or lethal (.100 µg/mL) range. 
Additional common adverse effects include cutaneous 
rashes, nausea, vomiting, and constipation. Idiosyncratic 
hypersensitivity reactions to phenytoin may consist of blood 
dyscrasias, including agranulocytosis, Hodgkin’s lymphoma, 
and pancytopenia.
Dermatological abnormalities, such as exfoliative der-
matitis, Stevens-Johnson syndrome, and toxic epidermal 
necrolysis, have also been observed. Phenytoin can induce 
cardiac abnormalities, such as arrhythmias, hepatitis, 
changes in blood glucose, and hypothyroidism. Chronic 
therapy has also been associated with behavioral changes, 
cognitive impairments, cerebellar ataxia, skin thickening, 
fat redistribution, gingival hyperplasia, hirsuitism, acne, and 
osteomalacia.1
valproic acid
Valproic acid has antiseizure activity equivalent to that of 
phenytoin in the treatment of complex partial seizures, with 
similar response rates of approximately 20%–50%.8,11 It is 
commercially available in different forms, including the free 
acid form (valproic acid), its sodium salt (sodium valproate), 
and a coordinated sodium salt complex (divalproex sodium), 
each with slightly different formulations and pharmacokinetic 
properties, but with equivalent pharmacological effects. The 
extent of absorption is equivalent for all formulations, each 
having a bioavailability of approximately 100%. Both food 
and the formulation affect the rate of drug absorption and 
can lead to differences in Cmax and tmax values, with altera-
tions of gastrointestinal pH affecting drug bioavailability. 
Valproic acid has saturable protein binding that produces 
nonproportional changes in drug effects and adverse effects 
at the upper range of therapeutic drug concentrations. 
A serum valproic acid concentration range of 50–100 µg/mL 
is typically associated with optimal antiseizure effects, and 
concentrations .100–125 µg/mL have been associated 
with increased frequency and severity of adverse effects. 
Adequate seizure control is achieved in some patients at 
higher than normal concentrations, and efficacy and adverse 
effects should be monitored, with dose regimen adjustments 
made on a case-by-case basis. Valproic acid is extensively 
metabolized by hepatic enzymes other than those in the cyto-
chrome P450 (CYP) system, with less than 3% of the dose 
eliminated unchanged in the urine. It is involved in numerous 
drug interactions, the potential for which should be evalu-
ated when starting valproic acid therapy or at the initiation, 
termination, or adjustment of other medications.10
Valproic acid commonly induces gastrointestinal 
adverse effects, including nausea, vomiting, and abdominal 
pain, with the possibility for substantial weight gain in 
many patients. Adverse CNS effects are also common, and 
include tremors, headaches, somnolence, weakness, and 
dizziness, with rare reports of drug-induced encephalopathy. 
Serious hepatotoxicity and associated fatalities have been 
reported necessitating liver function testing, primarily at the 
initiation of therapy or with changes to a dosage regimen. 
Dermatological reactions have also been reported, including 
transient alopecia and skin rash, with rare reports of Stevens-
Johnson syndrome. Valproic acid has been associated with 
dose-dependent thrombocytopenia and infrequent instances 
of bone marrow suppression. Rare reports of multiorgan 
Table 2 Approximate antiseizure efficacy for the treatment of 
complex partial seizures using agents approved by the US Food 
and Drug Administration for use as monotherapy
Antiepileptic drug Approximate efficacy 
(patients with $50% 
decrease in seizure activity)
Phenytoin 30%–60%
valproic acid 20%–50%
Carbamazepine 20%–40%
Oxcarbazepine 20%–30%
Phenobarbital 30%–40%
Topiramate 20%–50%
Lamotrigine 10%–30%
Felbamate *
Note: *Felbamate efficacy is reported as an absolute decrease in seizure activity and 
not as a percentage of patients with at least a 50% decrease in seizure activity.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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system failure following initiation of valproic acid therapy 
also necessitate early monitoring and evaluation.1
Carbamazepine
Carbamazepine has also demonstrated good seizure control, 
with a 20%–40% response rate, and equivalent activity to 
phenytoin and valproic acid in the management of complex 
partial seizures.8,12 The absorption of carbamazepine is slow 
and variable following oral administration, leading to vari-
able Cmax and tmax values. It has clinically insignificant protein 
binding, is substantially distributed throughout the body, and 
has cerebrospinal concentrations approximately equal to free 
drug concentrations in the blood, supporting a rationale for 
serum drug level testing.
Carbamazepine is extensively metabolized, and sig-
nificantly induces its own metabolism over a period of 
3–5 weeks. This metabolic autoinduction shortens the 
elimination half-life from 72 hours to 12–17 hours, and 
necessitates dose adjustments, with a usual target therapeu-
tic window of 4–12 µg/mL. Carbamazepine has numerous 
clinically significant interactions with other AEDs, and 
medications should be evaluated when initiating therapy or 
making adjustments to this or other regimens.10
Commonly reported adverse effects of carbamazepine 
include neurosensory disturbances of vision, balance, and 
movement, as well as CNS effects, such as dizziness, head-
aches, confusion, nausea, and vomiting. On occasion, the 
drug may induce clinically relevant hyponatremia. Severe 
and potentially fatal cardiac disturbances have been rarely 
reported, including thromboembolic events, thrombophlebi-
tis, development of arrhythmias and atrioventricular block, 
congestive heart failure, edema, hypotension, syncope, 
and cardiac arrest. Transient leukopenia is the most com-
monly reported hematological adverse event associated 
with carbamazepine, necessitating periodic assessment of 
white blood cell counts and possible drug discontinuation if 
levels fall below critical predefined thresholds. Additional 
blood disorders, including agranulocytosis, aplastic anemia, 
pancytopenia, and thrombocytopenia have been noted with 
carbamazepine use.
Dermatological reactions have been associated with 
carbamazepine use and include photosensitivity and rashes. 
Exfoliative dermatitis, Stevens-Johnson syndrome, toxic 
epidermal necrolysis, and acute generalized exanthematous 
pustulosis are rare but serious conditions also sometimes 
associated with carbamazepine therapy.1 It has recently been 
recommended that patients of Asian descent be tested for 
the presence of an allele encoding for a human leukocyte 
antigen (HLA-B*1502) associated with increased risk of 
Stevens-Johnson syndrome if carbamazepine therapy is 
being considered.13 A risk evaluation and mitigation strategy 
(REMS) has been put in place for carbamazepine, due to the 
risk of cutaneous reactions and bone marrow   suppression. 
However, the only requirement is the distribution of a medi-
cation guide to the consumer.14
Oxcarbazepine
Oxcarbazepine is structurally similar to carbamazepine and 
exerts its primary antiepileptic activity through its active 
metabolite, the 10-monohydrate derivative. Oxcarbazepine 
has equivalent efficacy to phenytoin, valproic acid, and car-
bamazepine, with typical response rates of 20%–30%.8,15–17 
Some patients who have failed initial carbamazepine therapy 
have responded to oxcarbazepine. The drug is extensively 
metabolized, but avoids the enzymatic autoinduction of car-
bamazepine. It does have metabolism-based drug interactions 
through inhibition of CYP 2C19 and 3A4 in a dose-dependent 
manner, with mild induction of UDP-glucuronosyltrans-
ferase, that should be considered prior to therapy or when 
additional medications are added. Oxcarbazepine is almost 
exclusively eliminated renally as the10-monohydrate deriva-
tive metabolite or its derivatives, necessitating renal function 
monitoring with accompanying dose regimen adjustments in 
patients with renal impairment. Therapeutic drug monitoring 
is not routinely done.
The most commonly reported adverse effects associated 
with oxcarbazepine therapy include dizziness, headache, nau-
sea, vomiting, and fatigue. Movement or vision disturbances, 
upper respiratory tract infections, and nervousness are also 
commonly reported. A significant number of patients experi-
ence hyponatremia at a higher frequency with oxcarbazepine 
as compared with carbamazepine, but this is most often 
  asymptomatic. Unspecified rashes, Stevens-Johnson syn-
drome, and toxic epidermal necrolysis, as well as multiorgan 
hypersensitivity reactions, have been rarely reported to occur 
soon after therapy was initiated, and patients should be moni-
tored for such events after the start of oxcarbazepine use.1,10
Phenobarbital
Phenobarbital is a long-acting barbiturate sedative with an 
approximate 30%–40% response rate in the treatment of com-
plex partial seizures.8 While it is not inferior to phenytoin or 
carbamazepine, its adverse effect profile tends to limit therapy 
and lead to higher patient withdrawal rates. Phenobarbital has a 
very slow elimination half-life, which causes significant delays 
to observed changes in seizure activity following dose regimen Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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adjustments. Drug metabolism is extensive and   variable, with 
significant induction of hepatic enzyme systems, resulting in 
numerous drug interactions. Therapeutic drug monitoring 
is often recommended, with a target phenobarbital range of 
15–40 µg/mL. Concentrations .30 µg/mL are associated with 
an increased incidence of side effects.
The adverse effect profile of phenobarbital severely limits 
its clinical utility and often relegates it to a second-line or 
third-line agent in adults. Specifically, CNS depression is 
very common and typically leads to symptoms of sedation, 
drowsiness, dizziness, and lethargy. Long-term use may 
result in physical and psychological dependence, depres-
sion, and cognitive blunting. The possibilities of respiratory 
depression, hypothermia, coma, and death increase with 
phenobarbital concentrations .50 µg/mL. Hematologic, 
hepatic, and renal disorders have been reported, and should 
be evaluated through regular testing. Dermatological and 
connective tissue disorders have also been reported. Rare 
reports of severe drug hypersensitivity reactions, such as 
exfoliative dermatitis, Stevens-Johnson syndrome, and toxic 
epidermal necrolysis are possible.1,10
Topiramate
Topiramate has demonstrated efficacy against complex partial 
seizures, with significant reductions in seizure frequency in 
20%–50% of patients when used as monotherapy.16–18 Topi-
ramate has good bioavailability and saturable but clinically 
insignificant protein binding. It is eliminated renally, with 
prominent tubular reabsorption taking place, and as such, 
dosing regimen should be adjusted in patients with renal 
impairment. Although topiramate is metabolized by both 
phase 1 and phase 2 reactions without significant hepatic 
contributions to elimination, it has been associated with 
metabolism-based drug interactions and should be used with 
caution if potential interactions are possible.10
CNS effects are the most prevalent adverse events asso-
ciated with topiramate therapy, and include somnolence, 
dizziness, fatigue, paresthesia, and nervousness, with move-
ment, cognitive, and psychological changes also frequently 
reported. Topiramate has been associated with the devel-
opment of metabolic acidosis, and may be responsible for 
dose-dependent weight loss and anorexia following chronic 
use. Acute narrow-angle glaucoma and development of kid-
ney stones are much more common with topiramate therapy 
compared with the incidence in the general population. 
Topiramate can impair sweat production and affect body 
temperature regulation, particularly in pediatric and geriatric 
patients, thus increasing the possibility of hyperthermia.1 
Topiramate must be dispensed with a medication guide as 
part of an FDA-mandated REMS so as to educate patients 
on possible adverse effects.14
Lamotrigine
Lamotrigine has been shown to have a 10%–30% patient 
response rate in the treatment of complex partial seizures, 
with high adherence rates due in part to less severe adverse 
effects compared with other AEDs.15,17 Comparative stud-
ies with phenytoin and carbamazepine have shown that 
lamotrigine produces similar reductions in seizure activity.16 
Other studies report only moderate comparative efficacy with 
alternative monotherapy agents.8 Lamotrigine has excellent 
oral bioavailability and clinically insignificant protein bind-
ing. Extensive UDP-glucuronosyltransferase-based hepatic 
metabolism followed by renal elimination has led to the 
recommendation of close monitoring for patients with severe 
renal or hepatic disease. Lamotrigine pharmacotherapy is 
sensitive to alterations in enzyme function and clearance 
mechanisms, with dose adjustments potentially necessary 
in the presence of other AEDs.10
Many of the adverse effects of lamotrigine are concen-
tration-dependent. The most common adverse effects include 
dizziness, headache, weakness, rash, nausea, somnolence, 
and vision disturbances. Some adverse effects occur more 
frequently when administered with other AEDs, for example, 
diplopia with carbamazepine and tremor with valproic acid. 
Dermatological rashes are often experienced near initiation 
of therapy. These can be serious, are often age-related, and 
may be minimized through slow dose titration to therapeutic 
effects.1 Lamotrigine must be dispensed with a mandatory 
medication guide for patient education as part of a REMS.14
Felbamate
Felbamate is highly efficacious as monotherapy or adjunc-
tive therapy in the treatment of complex partial seizures.19 
However, postmarketing reports have associated felbamate 
therapy with aplastic anemia and acute liver failure, includ-
ing some patient fatalities.20 These serious adverse effects 
occurred at a much higher frequency than is seen in the 
general population, and are estimated to be 1/3,000 for aplas-
tic anemia and 1/10,000 for hepatic failure, with possibly 
higher rates in children and in those with other comorbid 
factors.1,21 Patients and prescribers should sign an informed 
consent form related to these serious adverse effects prior 
to initiating therapy. However, this form is not required by 
the FDA as part of a REMS and is kept with the prescriber. 
No dispensing restrictions or   monitoring   parameters Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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are imposed by the FDA. Aside from these serious effects, 
felbamate is generally well tolerated, with common adverse 
effects of anorexia, weight loss, insomnia, nausea, and 
headache. Felbamate has favorable pharmacokinetic proper-
ties, but regimens should be adjusted in patients with renal 
dysfunction. The drug has been associated with numerous 
reported drug interactions that should be evaluated prior to 
initiation of felbamate therapy or any other drug. Therapeutic 
drug concentration monitoring is typically not required.10 
Clinically, felbamate is considered a last-line treatment option 
due to possibilities of serious and potentially fatal aplastic 
anemia and/or acute liver failure.
Adjunctive agents for complex 
partial seizures
Numerous agents have been approved by the FDA for the 
adjunctive treatment of complex partial seizures. These 
include gabapentin, pregabalin, tiagabine, levetiracetam, 
zonisamide, lacosamide, and vigabatrin. Most studies of 
these agents were conducted in treatment-refractory patients 
who had responder rates similar to the different AEDs.16–18 
However, these drugs are not easily compared to determine 
superiority due to different study designs and variations in 
inclusion criteria. Therefore, adjunctive therapeutic agent 
selection is typically determined by patient and provider 
preferences when comparing drug factors, including adverse 
effect profiles, clinical precautions, and possible drug 
interactions.
Gabapentin and pregabalin
Gabapentin and pregabalin are structurally and pharmaco-
logically similar, with comparable adverse effect profiles. 
Commonly reported effects include headache, dizziness, 
fatigue, drowsiness, depression, psychological changes, and 
movement disturbances. Additional adverse effects include 
substantial weight gain, a high incidence of peripheral edema 
that might precipitate dyspnea, vision disturbances, and 
rare reports of hypersensitivity reactions or blood disorders. 
Gabapentin and pregabalin are almost exclusively eliminated 
renally and should be used with caution in patients with renal 
dysfunction. These agents have virtually no drug interac-
tions due to the avoidance of hepatic metabolism and clini-
cally insignificant protein binding.1,10 Both gabapentin and 
pregabalin have patient education-based medication guides 
as part of their approved labeling. The guide for gabapentin 
must be provided to the patient as part of a REMS for the 
drug. However, the REMS originally in place for pregabalin, 
which also required presentation of the medication guide to 
the consumer, was nullified by the FDA as of early 2011, 
because the risk of use of the drug was no longer felt to 
outweigh the potential benefits.14,22
Tiagabine
Tiagabine has been associated with dizziness, fatigue, 
drowsiness, irritability, and mood and movement distur-
bances, with infrequent reports of moderate to severely 
debilitating weakness. Tiagabine is also reported to cause 
cognitive impairments and stupor, with altered cortical 
electrical conduction. These electrical abnormalities might 
be indicative of altered seizure activity, and warrant special 
consideration for tiagabine use and avoidance of medica-
tions that lower the seizure threshold. Drug interactions with 
tiagabine are primarily associated with its role as a substrate 
for CYP 3A4. It does not inhibit or induce hepatic enzymes, 
nor does it interact through competitive protein binding.1,10 
Tiagabine must be dispensed with a medication guide for 
patient education according to a REMS.14
Levetiracetam
Levetiracetam therapy is commonly associated with headache, 
drowsiness, sedation, weakness, movement disturbances, 
behavioral disturbances such as agitation or hostility, hair 
loss, loss of appetite, vomiting, and weight loss. Clinically 
significant blood disorders such as leukopenia, neutropenia, 
pancytopenia, and thrombocytopenia have been reported and 
warrant monitoring. Rare reports of pancreatitis and hepatitis 
have been associated with levetiracetam therapy and warrant 
additional monitoring. Renal function should be evaluated 
and appropriate dose adjustments made in patients with renal 
dysfunction taking levetiracetam, due to its extensive renal 
elimination by glomerular filtration. Levetiracetam is asso-
ciated with minimal drug interactions.1,10 Patients receiving 
levetiracetam must receive an educational medication guide 
as mandated by a REMS.14
Zonisamide
Zonisamide has an adverse effect profile, much like topi-
ramate, due in part to the presence of similar chemical 
moieties.23 Specifically, zonisamide is associated with 
sedation, dizziness, cognitive impairment, headache, vision 
disturbances, irritability, nausea, weight loss, and possible 
impairment of sweat production with accompanying changes 
in temperature regulation. Patients should be monitored for 
signs and symptoms of metabolic acidosis and be counseled 
to increase fluid intake to avoid the formation of kidney stones 
if they are susceptible. Hypersensitivity reactions are rare, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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but have been reported and include severe   conditions, such 
as toxic epidermal necrolysis, Stevens-Johnson syndrome, 
fulminant hepatic necrosis, agranulocytosis, aplastic anemia, 
and other blood disorders. Zonisamide does not have clini-
cally relevant competitive protein binding interactions with 
other drugs. It does not inhibit or induce hepatic enzymes, 
but is substantially metabolized by CYP 3A4 and UDP-
glucuronosyltransferase, and is involved in several clinically 
relevant drug interactions.1,10 A medication guide must be 
dispensed with zonisamide as part of a REMS according to 
FDA mandate.14
Lacosamide
Lacosamide is a newer AED that has not been included in 
meta-analyses or AED-based therapeutic reviews, but it 
has similar reported response rates as compared with other 
AEDs.24 It is associated with adverse CNS effects similar to 
other agents, with dizziness, headache, fatigue, movement 
disturbances, vision disturbances, and psychological changes 
having been reported. Lacosamide also causes nausea, vomit-
ing, and easy bruising. There have been reports of euphoria 
and psychological dependence following use. Potentially 
serious cardiac arrhythmias have been reported, and patients 
should be monitored with special precautions taken if comor-
bid cardiac disease is present. An isolated case of delayed 
multisystem hypersensitivity was reported in clinical trials, 
and additional reports of hepatitis, hepatic dysfunction, rash, 
and myocarditis have also been noted.25 Lacosamide is a 
CYP 2C19 substrate, but does not inhibit or induce hepatic 
enzymes. It is extensively eliminated renally, and requires 
renal function monitoring and dose regimen adjustments in 
patients with severe renal impairment.1,10 Lacosamide must 
also be dispensed with a patient medication guide due to 
REMS’ requirements.14
Use of vigabatrin for refractory 
partial seizures
Vigabatrin was approved in 2009 by the FDA following 
lengthy regulatory discussions and clinical studies, with 
an indication of adjunctive treatment for complex partial 
seizures in adults. This indication is based on numerous 
prospective, double-blind, placebo-controlled trials, in 
which its efficacy has been clearly demonstrated.26,27 Positive 
response rates, defined as a reduction in seizure frequency 
of $50%, were observed in 24%–67% of patients.26,28,29 
These robust response rates occurred consistently, despite 
differing inclusion criteria, varied adjunctive vigabatrin 
doses (although 3 g/day was the most common dose studied), 
diverse concomitant AED use, wide-ranging study lengths, 
and nonuniform study designs. Within these studies, subject 
retention rates were equivalent or superior to rates reported 
with other AEDs, which indicates that vigabatrin therapy is 
well tolerated.
Vigabatrin is rapidly and thoroughly absorbed following 
oral administration. It has negligible protein binding, with 
virtually no hepatic metabolism. Vigabatrin is eliminated 
primarily by the kidneys, and dosage regimen adjustments 
are necessary in patients with renal dysfunction. The few 
reported drug interactions with vigabatrin are minor, and 
vigabatrin does not require therapeutic adjustment when 
administered concomitantly with other AEDs.30
The adverse effect profile of vigabatrin requires special con-
siderations that come with rigorous monitoring   requirements. 
Vigabatrin has a lower reported incidence of adverse CNS 
effects common to other AEDs, including headache, drowsi-
ness, sedation, and fatigue.31 Adverse psychiatric effects 
associated with vigabatrin therapy tend to be more prevalent 
than with most other AEDs, and include agitation, depres-
sion, anxiety, emotional lability, psychosis, and mania.32 
However, these psychiatric disturbances are usually mild 
or have subtle symptomatology. Even so, they have been 
associated with treatment withdrawal, and patients should 
be monitored for such events.
There have been serious and frequent reports of idiosyn-
cratic permanent visual field loss with vigabatrin. Because of 
this, vision testing prior to therapy and regularly throughout 
therapy is an FDA requirement. This visual field loss was 
originally reported to occur in approximately 30% of patients, 
based on controlled studies that were primarily intended to 
evaluate antiseizure efficacy rather than adverse effects.33 
However, a recent review of all available studies involving 
vigabatrin therapy suggested a median incidence of 45%.34 It 
should be noted that up to 90% of patients who present with 
measurable visual field loss are asymptomatic.35 The varia-
tion in reported incidences might be attributable to differing 
detection methodologies, variances in patient enrollment, and 
nonuniform researcher reporting methods.
As part of the drug’s approval process, a restrictive REMS 
was mandated by the FDA to monitor and track permanent 
visual field loss associated with vigabatrin therapy.14 This 
REMS requires numerous steps that must take place prior 
to the initiation of therapy.36 These include presentation of a 
patient medication guide, baseline vision testing, prescriber 
enrollment with accompanying education, and patient con-
sent and education. The FDA also currently restricts the 
dispensing of vigabatrin prescriptions to four mail-order Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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pharmacies in the US with prescription orders, refills, and 
third-party reimbursements facilitated through a program 
referred to as Support, Help and Resources for Epilepsy 
(SHARE). A second patient consent is required if therapy 
is found to be efficacious and is expected to continue after 
an initial trial of up to 12 weeks.27 This trial duration is con-
sidered safe because the earliest reported incidence of visual 
field loss in an adult is after nine months of vigabatrin use.37 
The REMS also mandates quarterly testing for visual field 
loss, with accompanying documentation as managed by the 
SHARE program in order for vigabatrin therapy to continue. 
Finally, the REMS mandates final vision testing within 
3–6 months following discontinuation of vigabatrin therapy. 
Ultimately, therapeutic decisions involving vigabatrin when 
visual field loss has occurred are made by the provider and 
patient. Failure to follow guidelines for regular vision test-
ing requirements and accompanying documentation could 
result in eventual discontinuation of therapy as mandated 
by the SHARE program. This restrictive REMS is unlike 
that imposed on any other AED, and its implementation has 
resulted in dramatically increased costs for therapy in the US 
as compared with other countries.
Comparative AED analysis
There are only a few published AED comparisons focused on 
antiseizure efficacy in complex partial seizures or refractory 
epilepsy and they tend to be based on the systematic review 
of drug-focused reports or studies rather than on head-to-head 
comparisons in controlled clinical trials.7,11,12,15–18,38–41 The 
clinical conclusions drawn from these reviews are limited 
and sometimes conflicting, due in part to the design, patient 
characteristics, comparators, and reporting variability in the 
original studies as well as systematic reviews.42 However, 
most AEDs are considered therapeutically equivalent in a 
broad sense when used in difficult to treat seizures. In the 
limited studies that have prospectively and directly compared 
AEDs in patients with difficult to treat seizures, the efficacy 
and long-term adverse effects of carbamazepine were 
superior to those reported for valproic acid and phenobar-
bital, but were approximately equivalent to phenytoin.43,44 
Separate studies demonstrated that lamotrigine and tiagabine 
are equivalent, while levetiracetam has equivalent antiseizure 
activity but produces a faster response than topiramate in 
complex partial seizures.45,46 As previously discussed, drug 
antiseizure efficacy must be balanced with the potential for 
drug interactions, adverse effect profile, and numerous patient 
factors, such as renal and hepatic function. Therefore, the 
place of vigabatrin in the treatment of refractory complex 
partial seizures will be based on the balancing of clinical 
risks and possible patient benefits.
Conclusion
There is an extensive body of literature supporting the 
efficacy of vigabatrin in refractory complex partial seizures 
because the drug has been in clinical use outside the US 
since the 1980s. However, the discovery of permanent visual 
field loss and a high incidence of psychiatric disturbances 
have relegated its use far down the line within the realm of 
AED therapy for resistant epilepsy. Even so, vigabatrin is a 
welcome addition to the treatment options for refractory com-
plex partial seizures. Prescriber and patient comfort, along 
with the serious adverse effects associated with vigabatrin, 
will ultimately impact its place in the treatment of complex 
partial seizures.
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